HPTN 083: Safety, Efficacy, and Gender-Affirming Hormonal Therapy Interactions With Long-Acting Injectable CAB for HIV PrEP in Transgender Women

July 29-August 2, 2022; Montreal, Quebec
Gender-affirming hormonal therapy did not appear to affect cabotegravir concentrations in transgender women in this preliminary analysis from HPTN 083.
Format: Microsoft PowerPoint (.ppt)
File Size: 196 KB
Released: August 1, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Gilead Sciences, Inc.
ViiV Healthcare

Related Content

Review the latest data on ART safety and tolerability in special populations in this slideset, from Clinical Care Options (CCO)

Jean Rene Anderson, MD Jill Blumenthal, MD, MAS Marta Boffito, MD, PhD, FRCP Jennifer Cocohoba Headshot Jennifer Cocohoba, PharmD Julian Falutz, MD, FRCPC Priscilla Y. Hsue, MD Jens D. Lundgren, MD, DMSc William R. Short, MD, MPH, AAHIVS Released: September 30, 2022

Dr William R. Short: key considerations for the use of long-acting cabotegravir and rilpivirine in pregnancy, from Clinical Care Options (CCO)

William R. Short, MD, MPH, AAHIVS Released: September 28, 2022

Expert selections of important HIV data from AIDS 2022, including current and investigational strategies for prevention, ART, comorbidities, and cure

Joseph J. Eron, Jr., MD Jeffrey Kwong, DNP, MPH, FAANP, FAAN Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP David A. Wohl, MD Released: September 23, 2022

Expert selections of important HIV data from AIDS 2022, including current and investigational strategies for prevention, ART, and comorbidities

Jeffrey Kwong, DNP, MPH, FAANP, FAAN Released: September 23, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings